MHRA — authorised 9 November 2016
- Marketing authorisation holder: Pfizer Limited
- Status: approved
🇬🇧 Ibrance in United Kingdom
MHRA authorised Ibrance on 9 November 2016 · NICE has issued 2 UK HTA decisions
Marketing authorisation
Health technology assessment
2 decisions from NICE for Ibrance in United Kingdom.
NICE TA836 — ✓ Recommended
- Indication assessed: NICE technology appraisal guidance 836
NICE technology appraisal guidance 836 recommended Ibrance for use in the UK. This decision was made for the treatment of hormone receptor-positive human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. The cost basis of this decision is not reported.
NICE TA495 — ✓ Recommended
- Indication assessed: previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE recommended Ibrance for the treatment of previously untreated hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. This decision was made based on a commercial arrangement and a Patient Access Scheme. No restrictions were placed on the use of Ibrance.
Ibrance in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Ibrance approved in United Kingdom?
Yes. MHRA authorised it on 9 November 2016.
Who is the marketing authorisation holder for Ibrance in United Kingdom?
Pfizer Limited holds the UK marketing authorisation.
Has Ibrance been assessed by UK health technology agencies?
Yes — 2 UK HTA decisions on record from NICE.